Dr. Orest Lastow is the founder and CTO of Iconovo AB. He is also the former CEO of Iconovo and is the inventor of Iconovo’s four inhalation device platforms. He is also the founder and previous CEO of Medicon Valley Inhalation Consortium, MVIC AB. Orest was with AstraZeneca for over 15 years and is the principal inventor of AstraZeneca’s new dry powder inhalation platform. Orest is the inventor behind over 40 patents and patent applications.
Orest received a M.Sc. in Engineering Physics and a Licentiate of Engineering degree in Aerosol Science from Lund University. He has also a Ph.D. in electrohydrodynamic atomisation from Brunel University. His expertise is device development, electrostatics, Computational Fluid Dynamics (CFD), aerosol science and inhalation technology. He is the author behind a textbook on EHD atomisation, several journal publications and book contributions. He is frequently invited to speak at conferences and teaches aerosol drug delivery at Lund University and Copenhagen University. Orest is a co-author of the Aerosol drug delivery device design verification standard (ISO 20072).
Generic versions of marketed dry powder inhaler (DPI) drug products represent an attractive market opportunity. In the coming years, GSK’s Ellipta platform is the largest opportunity with several drug substance patents expiring. However, development of generic DPI drug products is a complicated process with many challenges. Complex drug-device interactions represent a major hurdle to achieve therapeutic equivalence. The very intricate patent landscape in combination with the requirement of similar user-handling and flow resistance limits the design options. The need for cost-efficient development and low manufacturing costs adds additional complexity. There is a great need to replace injections with safe and low cost inhaled drug delivery. Iconovo’s unit-dose inhaler ICOone is currently used in two ongoing projects on inhaled oxytocin and inhaled covid-19 vaccine.